POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT05932654. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Multicenter, Proof-of-Concept Clinical Trial to Evaluate Efficacy and Safety of BSI-045B mAb Injection in Patients With Moderate to Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The study is a multicenter clinical trial and is designed as a proof-of-concept study to evaluate the efficacy, safety, tolerability, PK, immunogenicity, and PD of BSI-045B following SC injections. The study will enroll patients with moderate to severe AD to receive the 300 mg treatment. BSI-045B wil be firstly given weekly during Week 1 to Week 4, and then every 2 weeks (Q2W) to Week 24.
Study identification
- NCT ID
- NCT05932654
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 22 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2023 (Actual)
- Primary completion
- Sep 18, 2024 (Actual)
- Completion
- Sep 18, 2024 (Actual)
- Last update posted
- Oct 15, 2025
2023 – 2024
United States locations
- U.S. sites
- 17
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| First OC Dermatology - Fountain Valley | Fountain Valley | California | 92708 | — |
| Center for Dermatology Clinical Research | Fremont | California | 94538 | — |
| Profound Research LLC - Nashville - Corporate | Oceanside | California | 92056 | — |
| The George Washington University School of Medicine and Health Science | Washington D.C. | District of Columbia | 20037 | — |
| Advanced Medical Research - Medical Dermatology Specialists | Sandy Springs | Georgia | 30328 | — |
| Dawes Fretzin Clinical Research | Indianapolis | Indiana | 46250 | — |
| Skin Sciences/Derm Research Pllc. | Louisville | Kentucky | 40217 | — |
| Allcutis Research - Beverly, MA | Beverly | Massachusetts | 01915 | — |
| Beacon Clinical Research | Quincy | Massachusetts | 02169 | — |
| Sadick Research Group | New York | New York | 10075 | — |
| Accellacare - Cary | Cary | North Carolina | 27518 | — |
| Accellacare - Raleigh | Raleigh | North Carolina | 27609 | — |
| Accellacare-Wilmington | Wilmington | North Carolina | 28411 | — |
| Wright State Physicians Health Center | Fairborn | Ohio | 45324 | — |
| Paddington Testing Company | Philadelphia | Pennsylvania | 19103 | — |
| Center for Clinical Studies - Webster | Webster | Texas | 77598 | — |
| Dermatology Specialists of Spokane | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05932654, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05932654 live on ClinicalTrials.gov.